VISEN PHARMA-B (02561) announced its interim results for the six months ended June 30, 2025, recording other income of RMB 5.301 million during the period. Research and development costs reached RMB 46.621 million, representing a 19.8% year-on-year increase.

According to the announcement, during the interim period, the Group has been collaborating with WuXi Biologics (the Group's designated local CDMO in China) on the commercial production of lonapegsomatropin. In July 2023, the Group entered into a master technology transfer plan with Ascendis Pharma for its core product, marking the commencement of technology transfer from Ascendis Pharma to the Group regarding core product manufacturing.

In December 2023, the Group signed a collaboration agreement with WuXi Biologics, under which WuXi Biologics will serve as the local CDMO for technology transfer, conducting process development and validation to achieve localization of production technology. As of June 2025, the technology transfer pilot studies for key reagents and intermediates have been completed. The Group aims to complete the technology transfer pilot studies for the core product drug substance by the end of 2025 or earlier. The complete technology transfer and localization is expected to be finished by 2027, which will enable the Group to collaborate with WuXi Biologics in producing the core product drug substance.